IPO - CytomX Therapeutics, Inc.

Form Type: 8-K

Filing Date: 2025-05-13

Corporate Action: Ipo

Type: New

Accession Number: 000119312525118805

Filing Summary: On May 12, 2025, CytomX Therapeutics, Inc. entered into an underwriting agreement with Jefferies LLC and Piper Sandler & Co. for the offering of 76,923,076 shares of its common stock at an offering price of $1.30 per share. The closing of the offering occurred on May 13, 2025. The estimated net proceeds from the offering are approximately $93.4 million, which will be used for research and development, general corporate purposes, and working capital needs. The Underwriting Agreement includes customary representations, warranties, and agreements, as well as indemnification obligations related to liabilities under the Securities Act of 1933. The agreement and related legal opinion by Latham & Watkins LLP are attached as exhibits to the filing.